News and publications

Pfizer’s Billions: A Russian Patent Showdown

In a significant legal development within the pharmaceutical landscape, Pfizer, the American pharmaceutical giant, has initiated a legal battle in Russia to claim over 12.5 billion rubles from Nativa, a company currently undergoing bankruptcy proceedings. This substantial claim is believed to encompass the financial losses that Pfizer asserts it incurred due to the sale of a generic version of its anti-tumor medication, sunitinib, by Nativa.
The indicated legal dispute between Pfizer and Nativa is rooted in the alleged patent infringement related to Sunitinib-Native, a generic version of Pfizer’s oncological drug, Sutent. Notably, Nativa began marketing this generic in 2017, while Pfizer’s patent for sunitinib, the active component within Sutent, was still in effect until August 31, 2022. Pfizer had previously engaged in legal disputes with Nativa over patent infringements, aiming to terminate the production and distribution of Sunitinib-Native. The court initially ruled in favor of Nativa, granting them a compulsory license for sunitinib in exchange for annual payments to Pfizer, amounting to 10% of the product’s sales revenue. It was only in October 2022 that Pfizer successfully challenged this decision on appeal.
In the most recent development, the court granted Pfizer Innovations’ request for information from Nativa about the quantity and pricing of Sunitinib-Native, which has been available in the market since March 2017. Sunitinib-Native has remarkably overtaken the original Sutent in sales since 2019 – 8.12 billion rubles vs 4.88 billion rubles through state procurement between 2018 and 2022.
Current complex patent dispute extends to Nativa’s prior legal conflicts with prominent pharmaceutical entities, including BMS, Celgene, and AstraZeneca. By the time bankruptcy proceedings were initiated, Nativa no longer held valid certificates for its pharmaceutical products. As a result, some of these certificates, including sunitinib, were transferred to Pharmmental Group in 2021.
In the legal battle with Pfizer, Nativa’s insolvency adds complexity to the case, raising questions about the practicality of recovering substantial damages.

pat

Recent Posts

Eduard Shablin, Partner at Patentica, participated in roving seminar of the Eurasian Patent Office in China

From March 17 to 21, a delegation from the Eurasian Patent Office (EAPO), together with…

3 дня ago

Revolutionary Impact of AI in the Ski Resort Industry

The full-scale implementation of artificial intelligence (AI) in the ski industry is transformative. Sber has…

2 недели ago

Impressive Achievements of the Eurasian Patent Office in 2024

In 2024, the Eurasian Patent Office (EAPO) saw remarkable growth, receiving 3,252 Eurasian applications for…

3 недели ago

New Patent Regulations in Ukraine: Key Changes and Considerations

As of September 18, 2024, the National Office of Intellectual Property and Innovations of Ukraine…

1 месяц ago

Achieving New Heights: Boosting Kazakhstan’s Innovative Potential

In recent years, Kazakhstan has experienced notable economic growth, driven by the stable development of…

2 месяца ago

A well-deserved trademark registration

Many trademarks may include non-protectable elements, which describe the type of goods these marks are…

2 месяца ago